Thomas Holm Pedersen, NMD Pharma CEO
November 15, 2023 10:20 AM EST
Financing
Startups

NMD Phar­ma se­cures €75M from in­sid­ers for three PhII tri­als in neu­ro­mus­cu­lar dis­or­ders

Kyle LaHucik

Senior Reporter

Dan­ish biotech NMD Phar­ma, named for its fo­cus on neu­ro­mus­cu­lar dis­or­ders, has tacked on €75 mil­lion ($81 mil­lion) to bankroll three Phase II stud­ies of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Evotec gains on Halozyme's takeover pro­pos­al

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times